{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:09:35Z","timestamp":1788480575530,"version":"build-2803163510"},"reference-count":41,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institute of Health Research","doi-asserted-by":"crossref","award":["PJT 162219"],"award-info":[{"award-number":["PJT 162219"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,10,6]]},"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inflammation is a key mediator in the development and progression of the atherosclerotic disease process as well as its resultant complications, like myocardial infarction (MI), stroke and cardiovascular (CV) death, and is emerging as a novel treatment target. Trials involving anti-inflammatory medications have demonstrated outcome benefit in patients with known CV disease. In this regard, colchicine appears to hold great promise. However, there are potential drawbacks to colchicine use, as some studies have identified an increased risk of infection, and a non-significant trend for increased all-cause mortality. Thus, a more thorough understanding of the underlying mechanism of action of colchicine is needed to enable a better patient selection for this novel CV therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      The primary objective of the Canadian Study of Arterial Inflammation in Patients with Diabetes and Recent Vascular Events, Evaluation of Colchicine Effectiveness (CADENCE) trial is to assess the effect of colchicine on vascular inflammation in the carotid arteries and ascending aorta measured with\n                      <jats:sup>18<\/jats:sup>\n                      F-fluorodeoxyglucose (FDG) positron emission tomography (PET)\/CT in patients with type 2 diabetes mellitus (T2DM) or pre-diabetes who have experienced a recent vascular event (acute coronary syndrome (ACS)\/MI, transient ischaemic attack (TIA) or stroke). Secondary objectives include determining colchicine\u2019s effect on inflammatory biomarkers (high-sensitivity C reactive protein (hs-CRP) and interleukin-6 (IL-6)). Additionally, we will assess if baseline inflammation imaging or biomarkers are associated with a treatment response to colchicine determined by imaging. Exploratory objectives will look at: (1) the difference in the inflammatory response to colchicine in patients with coronary events compared with patients with cerebral events; (2) the difference in the inflammatory response to colchicine in different vascular beds; (3) the relationship of FDG-PET imaging markers with serum biomarkers and (4) assessment of quality-of-life changes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and design<\/jats:title>\n                    <jats:p>\n                      CADENCE is a multicentre, prospective, randomised, double-blinded, placebo-controlled study to determine the effect of colchicine on arterial inflammation as assessed with imaging and circulatory biomarkers, specifically carotid arteries and aortic FDG uptake as well as hs-CRP and IL-6 among others. Patients with T2DM or pre-diabetes who have recently experienced a CV event (within 30\u2013120 days after an ACS (ie, ST-elevation MI (STEMI) or non-STEMI)) or TIA\/stroke with documented large vessel atherosclerotic disease will be randomised to treatment with either colchicine 0.6\u2009mg oral daily or placebo. Participants will undergo baseline clinical evaluation including EQ5D assessment, blood work for inflammatory markers and FDG PET\/CT scan of the ascending aorta and left and right carotid arteries. Patients will undergo treatment for 6 months and have repeat clinical evaluation including EQ5D assessment, blood work for inflammatory markers and FDG PET\/CT scan at the conclusion of the study. The primary outcome will be the change in the maximum target to background ratio (TBR\n                      <jats:sub>max<\/jats:sub>\n                      ) in the ascending aorta (or carotid arteries) from baseline to follow-up on FDG PET\/CT imaging.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Colchicine is an exciting potential new therapy for CV risk reduction. However, its use is associated with side effects and greater understanding of its underlying mechanism of action is needed. Importantly, the current study will determine whether its anti-inflammatory action is an indirect systemic effect, or a more local plaque action that decreases inflammation. The results will also help identify patients who will benefit most from such therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04181996\">NCT04181996<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-074463","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T12:07:28Z","timestamp":1699618048000},"page":"e074463","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["The Canadian Study of Arterial Inflammation in Patients with Diabetes and Recent Vascular Events, Evaluation of Colchicine Effectiveness (CADENCE): protocol for a randomised, double-blind, placebo-controlled trial"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct04181996","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9449-9372","authenticated-orcid":false,"given":"Kevin Emery","family":"Boczar","sequence":"first","affiliation":[{"name":"University of Ottawa Heart Institute, Ottawa, Ontario, Canada"},{"name":"Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheojung","family":"Shin","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"deKemp","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dar","family":"Dowlatshahi","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Ottawa Hospital, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahita","family":"Tavoosi","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Wiefels","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Liu","sequence":"additional","affiliation":[{"name":"University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Lochnan","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A","family":"MacPherson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Ottawa Hospital General Campus, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aun Yeong","family":"Chong","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Torres","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Leung","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Tawakol","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ahmadi","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Garrard","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Lefebvre","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Kelly","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poppy","family":"MacPhee","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everad","family":"Tilokee","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Raggi","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A","family":"Wells","sequence":"additional","affiliation":[{"name":"School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Beanlands","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute, Ottawa, Ontario, Canada"},{"name":"Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,11,10]]},"reference":[{"key":"2025121515013684000_13.11.e074463.1","first-page":"1553","article-title":"Hearts on fire: the role of inflammation in the pathogenesis of Atherosclerotic cardiovascular disease and how we can tend to the flames","volume":"38","author":"Boczar","year":"2022","journal-title":"Can J Cardiol"},{"key":"2025121515013684000_13.11.e074463.2","doi-asserted-by":"publisher","DOI":"10.1038\/nature01323"},{"key":"2025121515013684000_13.11.e074463.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707914"},{"key":"2025121515013684000_13.11.e074463.4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cjco.2022.01.003","article-title":"Cost-effectiveness of Canakinumab from a Canadian perspective for recurrent cardiovascular events","volume":"4","author":"Boczar","year":"2022","journal-title":"CJC Open"},{"key":"2025121515013684000_13.11.e074463.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021372"},{"key":"2025121515013684000_13.11.e074463.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912388"},{"key":"2025121515013684000_13.11.e074463.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(98)80028-0"},{"key":"2025121515013684000_13.11.e074463.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208536"},{"key":"2025121515013684000_13.11.e074463.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.27327"},{"key":"2025121515013684000_13.11.e074463.10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00296-018-04237-w","article-title":"Efficacy and safety of long-term treatment with intravenous Colchicine for familial Mediterranean fever (FMF) refractory to oral Colchicine","volume":"39","author":"Grossman","year":"2019","journal-title":"Rheumatol Int"},{"key":"2025121515013684000_13.11.e074463.11","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1161\/CIRCULATIONAHA.120.050771","article-title":"Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial","volume":"142","author":"Tong","year":"2020","journal-title":"Circulation"},{"key":"2025121515013684000_13.11.e074463.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2013.08.006"},{"key":"2025121515013684000_13.11.e074463.13","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000138"},{"key":"2025121515013684000_13.11.e074463.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.07.050"},{"key":"2025121515013684000_13.11.e074463.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.01.088"},{"key":"2025121515013684000_13.11.e074463.16","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"},{"key":"2025121515013684000_13.11.e074463.17","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ijcard.2018.05.057","article-title":"[18F]-Fluorodeoxyglucose PET\/CT imaging as a marker of carotid plaque inflammation: comparison to Immunohistology and relationship to acuity of events","volume":"271","author":"Cocker","year":"2018","journal-title":"Int J Cardiol"},{"key":"2025121515013684000_13.11.e074463.18","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1007\/s12350-021-02830-4","article-title":"Anti-inflammatory effect of Rosuvastatin in patients with HIV infection: an FDG-PET pilot study","volume":"29","author":"Boczar","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"2025121515013684000_13.11.e074463.19","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1007\/s12350-023-03204-8","article-title":"Anti-inflammatory effect of biologic therapy in patients with Psoriatic disease: A prospective cohort FDG PET study","volume":"30","author":"Boczar","year":"2023","journal-title":"J Nucl Cardiol"},{"key":"2025121515013684000_13.11.e074463.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.04.066"},{"key":"2025121515013684000_13.11.e074463.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2011.08.007"},{"key":"2025121515013684000_13.11.e074463.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.05.024"},{"key":"2025121515013684000_13.11.e074463.23","doi-asserted-by":"publisher","DOI":"10.1002\/prca.201400130"},{"key":"2025121515013684000_13.11.e074463.24","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000142812.03840.6f"},{"key":"2025121515013684000_13.11.e074463.25","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2015.04.818","article-title":"Association of circulating levels of Neopterin with non-culprit plaque vulnerability in CAD patients an angiogram, optical coherent tomography and Intravascular ultrasound study","volume":"241","author":"Sun","year":"2015","journal-title":"Atherosclerosis"},{"key":"2025121515013684000_13.11.e074463.26","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002563","article-title":"Level of pregnancy-associated plasma protein-A correlates with coronary thin-cap Fibroatheroma burden in patients with coronary artery disease: novel findings from 3-vessel virtual histology Intravascular ultrasound assessment","volume":"95","author":"Wu","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2025121515013684000_13.11.e074463.27","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1086\/675988","article-title":"Pentraxin-3 and the right ventricle: the multi-ethnic study of Atherosclerosis-right ventricle study","volume":"4","author":"Leary","year":"2014","journal-title":"Pulm Circ"},{"key":"2025121515013684000_13.11.e074463.28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.atherosclerosis.2016.02.013","article-title":"Relations of circulating GDF-15, soluble St2, and troponin-I concentrations with vascular function in the community: the Framingham heart study","volume":"248","author":"Andersson","year":"2016","journal-title":"Atherosclerosis"},{"key":"2025121515013684000_13.11.e074463.29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.115.304437"},{"key":"2025121515013684000_13.11.e074463.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.01.036"},{"key":"2025121515013684000_13.11.e074463.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(99)00463-3"},{"key":"2025121515013684000_13.11.e074463.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2010.05.002"},{"key":"2025121515013684000_13.11.e074463.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.07.043"},{"key":"2025121515013684000_13.11.e074463.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2013.11.007"},{"key":"2025121515013684000_13.11.e074463.35","doi-asserted-by":"publisher","DOI":"10.3109\/07853890109002087"},{"key":"2025121515013684000_13.11.e074463.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.10.027"},{"key":"2025121515013684000_13.11.e074463.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2012.02.016"},{"key":"2025121515013684000_13.11.e074463.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.03.039"},{"key":"2025121515013684000_13.11.e074463.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2025121515013684000_13.11.e074463.40","doi-asserted-by":"publisher","DOI":"10.1161\/hc0902.104353"},{"key":"2025121515013684000_13.11.e074463.41","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.semnuclmed.2020.02.005","article-title":"The future of cardiac molecular imaging","volume":"50","author":"Farber","year":"2020","journal-title":"Semin Nucl Med"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-074463","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T23:01:44Z","timestamp":1765839704000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-074463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":41,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,10]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1136\/bmjopen-2023-074463"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-074463","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}